Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

BACKGROUND: Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations. Patterns of CLL evolution under ibrutinib therapy are well characterized...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomark Res
Main Authors: Cadot, Sarah, Valle, Carine, Tosolini, Marie, Pont, Frederic, Largeaud, Laetitia, Laurent, Camille, Fournie, Jean Jacques, Ysebaert, Loic, Quillet-Mary, Anne
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724843/
https://ncbi.nlm.nih.gov/pubmed/33298182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00253-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados